Bicara Therapeutics shares rise 3% on trial enrollment progress

Bicara Therapeutics Inc. shares rose 3% in early trading on Tuesday after the biotech company reported progress in enrolling patients for its pivotal clinical trial.

The company, which focuses on developing treatments for inflammatory diseases, said it had reached a key milestone in patient recruitment for its phase 3 study evaluating an experimental therapy. Financial terms of the trial were not disclosed.

Bicara shares were up 3% at $12.45 in premarket trading, extending gains from Monday’s close. The stock has gained roughly 15% over the past month amid investor optimism surrounding the trial’s potential outcomes.

The phase 3 trial is designed to assess the safety and efficacy of the company’s lead candidate, BCA101, in treating a specific inflammatory condition. Enrollment progress is a critical step toward regulatory submissions and potential commercialization.

Analysts noted that successful trial completion could position Bicara for a significant valuation uplift, though risks remain given the high failure rate in late-stage drug development. No updates on trial timelines or data readouts were provided in the announcement.